Nanocapsulated Rift Valley fever vaccine candidates and relative immunological and histopathological reactivity in out bred sWiss mice

Journal of Vaccines and Vaccination

Volumn 2, Issue 1, 2011, Pages

  Abd el Razek, Noha Emad El Din ^a   Shoman, Sahar A ^a   Mohamed, Aly Fahmy ^a  

^a Holding Company for Biological Products   (Egypt)

Author keywords

Adjuvant activity; Adjuvant side effects; Alum; Nanoparticle CAP adjuvant; RVFV vaccine

Indexed keywords

EID: 84857016582     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000115     Document Type: Article

References (41)

1. Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, Dungu B, et al. (2007) Veterinary vaccines and their use in developing countries. Rev Sci Tech 26: 179-201.
2. WHO (2010) Safety and Immunogenicity Study of Rift Valley Fever Vaccine (RVF).
3. Gupta RK, Siber GR (1995) Adjuvants for human vaccine-current status, problems and feature prospects. Vaccine 13: 1263-1276.
4. Glenny AT, Pope CG, Waddington H, Wallace U (1926) The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 29: 38-45.
5. Vogel FR, Powell MF (1995) A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 6: 141-228.
6. Hem SL, White JL (1995) Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 6: 249-276.
7. He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, et al. (2000). Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 7: 899-903.
8. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug delivery rev 32: 155-172.
9. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, et al. (1993) Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270: 2935-2939.
10. Confavreux C, Suissa A, Saddier P, Bourdes V, Vukusic S, et al. (2001) Vaccinations and the risk of relapse of multiple sclerosis. Vaccines in Multiple Sclerosis Group. N Engl J Med 344: 319-326.
11. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, et al. (1998) Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15: 1-8.
12. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL (1999) Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29: 924-927.
13. Hadler S, Francis DP, Maynard JE (1986) Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315: 209-214.
14. Zhang L, FX Gu, JM Chan, AZ Wang, RS Langer, et al. (2008) Nanoparticles in Medicine: Therapeutic Applications and Developments. Clinical pharmacology and therapeutics 83: 761-769.
15. He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, et al. (2000) Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 7: 899-903.
16. Emerich DF, Thanos CG (2007) Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 15: 163-183.
17. Nikolai Petrovsky, Susanne Heinzel, Yoshikazu Honda, A. Bruce Lyons (2007) New-Age Vaccine Adjuvants: Friend or Foe? BioPharm International.
18. Aly FM, Mamoun AZ, Hekmat MT, Amal SM (2003) Comparative evaluation of different stability enhancer to liquid rabies vaccine at different thermal conditions. Egy Jour of Zoology 443-453.
19. Heba Ali, A El Gawad Hashem, O. El Tayeb, Aly Fahmy (2010) Evaluation of inactivation efficacy of Sabin Polio virus using different inactivating agents and its immunogenicity post nano and micro incapsulation. International journal of microbiological research 1: 114-122.
20. El-Karamany R, Imam I, Farid A (1981) Production of inactivated RVF vaccine. J Egypt Publ Health Assoc 56: 495-525.
21. Bussereau F, Benejean J, Saghi N (1982) Isolation and study of temperature sensitive mutants of rabies virus. GenVirol 60:153-158.
22. Madhusudana SN, Shamsundar R, Seetharaman S (2004) In Vitro inactivation of the rabies virus by ascorbic acid. Int J Infect Dis 8: 21-25.
23. Salo RJ, Cliver DO (1976) Effect of acid pH, salts, and temperature on the infectivity and physical integrity of enteroviruses. Arch Virol 52: 269-282.
24. El-Karamany RM (1987) Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. Acta Virol 31: 321-328.
25. Reed LT, Muench HA (1938) simple method of calculating fty percent end point. Am J Hyg 27: 493-498.
26. Ching FP, Omogbai EK, Ozolua RI, Okpo SO (2009): Analgesic activity of aqueous extract of stereospermum kunthianum (cham, sandrine petit) stem bark. Acta Pol Pharm 66: 83-88.
27. Ecobichon DJ (1997) The Basis of Toxiciology Testing. page 43, CRC Press, New York.
28. Salama LS (1991) Studies on the immune response of Rift valley fever vaccine. M Vsc Thesis Vet Med, Cairo University.
29. Gupta RK (1998) Aluminium compounds as vaccine adjuvants. Adv Drug Deliv Rev 32: 155-172.
30. Lindblad EB (1995) Aluminium adjuvants in theory and practical applicaton of adjuvants (Stewart-Tull, D.E.S., ed.), wiley, Chichester 21-35.
31. John D. Bancraft, Marilyn Gamble (2002) Theory and Practice of Histological Techniques. Fifth Edition, Churchill Livingstone; London, Edinburgh, New York, Philadelphia, St. Louis, Sydney, Toronto.
32. Mohamed F.A.; El-Kaschef A.H.; Reda I. M; Tantawey HM, Hassen RA (1997) Biological studies for the importance of Rift Valley Fever Vaccine. ph. D thesis, Suez Canal Univ Zool Department.
33. Behbehani AM, McMillen JK, Hiller MS, Wenner HA (1967): Effect of ß-Propiolactone on Adventitious Viruses in mouse immune ascetic fluids and sera. Appl Microbiol 15: 940-942.
34. Blackburn NK, Besselaar TG (1991) A study of the effect of chemical inactivants on the epitopes of Rift Valley Fever virus glycoproteins using monoclonal antibodies. J Virol Methods 33: 367-374.
35. WHO (1983) The use of veterinary vaccine for prevention and control of Rift valley fever. Memorandom form W H O/FAD meeting. Bull World Health Organ 61: 261-268.
36. Cullen EI, May V, Eipper BA (1986): Transport and stability of ascorbic acid in pituitary cultures. Mol Cell Endocrinol 48: 239-250.
37. WHO (1996) int/entity/rabies/vaccines/en/Laboratory_techniques_in_rabies_chapter25.
38. Lazarowicz M, Kihm U, Bommeli W, Zutter R (1982) Potency testing of inactivated rabies vaccines in mice, dogs and cats. Comp Immunol Microbiol Infect Dis 5: 233-235.
39. Habib M, Hussain I, Irshad H, Yang ZZ, Shuai JB, et al. (2006) Immunogenicity of formaldehyde and binary ethylenimine inactivated infectious bursal disease virus in broiler chicks. J Zhejiang Univ Sci B 7: 660-664.
40. Patel GB, Zhou H, Ponce A, Chen W (2009) Safety Evaluation of Calcium Administered Intranasally to Mice. Int J Toxicol 28: 510-518.
41. Q He, Z Fang, M Wang, QW Xu, R Chen, et al. (2008) Lyceum Chinese and Calcium Phosphate Nanoparticles for Ophthalmic Drug Delivery. Nanotech 2: 401-404.